The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, BJ Kuss, CS Tam, Z Gasztonyi, F Offner, S Lunin, F Bosch, MS Davids, N Lamanna, U Jaeger, P Ghia, F Cymbalista, CA Portell, AP SkarbnikAF Cashen, DT Weaver, VM Kelly, B Turnbull, S Stilgenbauer

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds